Dixon Hubard Feinour & Brown’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $6.32M | Sell |
120,468
-2,210
| -2% | -$113K | 0.75% | 47 |
|
|
2022
Q1 | $6.35M | Buy |
122,678
+7,536
| +7% | +$391K | 0.64% | 45 |
|
|
2021
Q4 | $6.8M | Buy |
115,142
+14,188
| +14% | +$703K | 0.65% | 48 |
|
|
2021
Q3 | $4.34M | Sell |
100,954
-8,810
| -8% | -$390K | 0.92% | 35 |
|
|
2021
Q2 | $4.3M | Sell |
109,764
-144,694
| -57% | -$5.63M | 0.89% | 34 |
|
|
2021
Q1 | $9.28M | Buy |
254,458
+124,950
| +96% | +$4.44M | 1.14% | 24 |
|
|
2020
Q4 | $4.75M | Sell |
129,508
-6,993
| -5% | -$257K | 1.22% | 26 |
|
|
2020
Q3 | $4.75M | Sell |
136,501
-20,575
| -13% | -$721K | 1.22% | 26 |
|
|
2020
Q2 | $5.82M | Buy |
157,076
+10,276
| +7% | +$349K | 1.51% | 25 |
|
|
2020
Q1 | $4.55M | Sell |
146,800
-935
| -0.6% | -$31.9K | 1.54% | 25 |
|
|
2019
Q4 | $5.49M | Sell |
147,735
-15,362
| -9% | -$547K | 1.43% | 25 |
|
|
2019
Q3 | $5.56M | Buy |
163,097
+1,000
| +0.6% | +$36.4K | 1.54% | 21 |
|
|
2019
Q2 | $6.66M | Buy |
162,097
+5,991
| +4% | +$238K | 1.89% | 16 |
|
|
2019
Q1 | $6.29M | Buy |
156,106
+5,172
| +3% | +$207K | 1.9% | 16 |
|
|
2018
Q4 | $6.25M | Buy |
150,934
+1,408
| +0.9% | +$58.4K | 2.31% | 11 |
|
|
2018
Q3 | $6.25M | Buy |
149,526
+1,797
| +1% | +$69.2K | 1.73% | 21 |
|
|
2018
Q2 | $5.08M | Buy |
147,729
+16,553
| +13% | +$566K | 1.48% | 25 |
|
|
2018
Q1 | $4.42M | Sell |
131,176
-6,441
| -5% | -$221K | 1.23% | 28 |
|
|
2017
Q4 | $4.73M | Buy |
137,617
+2,029
| +1% | +$69.2K | 1.28% | 29 |
|
|
2017
Q3 | $4.59M | Sell |
135,588
-3,372
| -2% | -$108K | 1.32% | 29 |
|
|
2017
Q2 | $4.43M | Sell |
138,960
-1,198
| -0.9% | -$37.8K | 1.28% | 28 |
|
|
2017
Q1 | $4.55M | Buy |
140,158
+264
| +0.2% | +$8.32K | 1.35% | 28 |
|
|
2016
Q4 | $4.31M | Sell |
139,894
-1,560
| -1% | -$47.6K | 1.37% | 28 |
|
|
2016
Q3 | $4.55M | Sell |
141,454
-23
| -0% | -$769 | 1.41% | 27 |
|
|
2016
Q2 | $4.73M | Sell |
141,477
-264
| -0.2% | -$8.43K | 1.51% | 24 |
|
|
2016
Q1 | $4.4M | Buy |
141,741
+2,187
| +2% | +$62.5K | 1.44% | 27 |
|
|
2015
Q4 | $4.27M | Buy |
139,554
+2,506
| +2% | +$78.8K | 1.36% | 30 |
|
|
2015
Q3 | $4.08M | Buy |
137,048
+2,109
| +2% | +$67.6K | 1.5% | 25 |
|
|
2015
Q2 | $4.29M | Buy |
134,939
+1,977
| +1% | +$64.4K | 1.32% | 32 |
|
|
2015
Q1 | $4.39M | Buy |
132,962
+2,472
| +2% | +$78.6K | 1.3% | 31 |
|
|
2014
Q4 | $3.86M | Buy |
130,490
+10,302
| +9% | +$295K | 1.2% | 32 |
|
|
2014
Q3 | $3.37M | Sell |
120,188
-1,039
| -0.9% | -$29.2K | 1.11% | 34 |
|
|
2014
Q2 | $3.41M | Buy |
121,227
+3,842
| +3% | +$110K | 1.12% | 35 |
|
|
2014
Q1 | $3.58M | Buy |
117,385
+14,360
| +14% | +$428K | 1.24% | 31 |
|
|
2013
Q4 | $2.99M | Sell |
103,025
-633
| -0.6% | -$18.4K | 1.11% | 36 |
|
|
2013
Q3 | $2.83M | Sell |
103,658
-3,315
| -3% | -$90.2K | 1.2% | 34 |
|
|
2013
Q2 | $2.84M | Buy |
+106,973
| New | +$2.96M | 1.27% | 31 |
|
Other funds holding PFE
Dixon Hubard Feinour & Brown's PFE Position: Q2 2022 in Review
Dixon Hubard Feinour & Brown reduced its Pfizer (PFE) stake by 1.8% in Q2 2022, selling an estimated $113K and leaving 120,468 shares worth $6.32M. The position accounts for 0.75% of the portfolio, ranked #47.
Dixon Hubard Feinour & Brown first reported a position in PFE in Q2 2013 and has held it in 37 quarters since. The position peaked at $9.28M in Q1 2021. 3,157 funds tracked by Wall St. Rank hold PFE as of Q2 2022.
- Dixon Hubard Feinour & Brown held 120,468 shares of Pfizer worth $6.32M as of Q2 2022.
- Dixon Hubard Feinour & Brown sold 2,210 Pfizer shares in Q2 2022, an estimated $113K.
- Pfizer made up 0.75% of Dixon Hubard Feinour & Brown's portfolio in Q2 2022, its #47 holding.
- Dixon Hubard Feinour & Brown first reported a position in Pfizer in Q2 2013 and has held it in 37 quarters since.
- Dixon Hubard Feinour & Brown's Pfizer position peaked at $9.28M in Q1 2021.
- 3,157 funds tracked by Wall St. Rank held Pfizer as of Q2 2022.
Based on Dixon Hubard Feinour & Brown's 13F filing for Q2 2022, filed 22 Jul 2022.